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Background: Chronic obstructive pulmonary disease (COPD) is frequently associated with 
comorbid depression and anxiety. Managing COPD symptoms and exacerbations through use 
of appropriate and adequate pharmacotherapy in this population may result in better COPD-
related outcomes.
Methods: This retrospective, observational study used administrative claims of patients aged 
40 years and older with COPD and comorbid depression/anxiety identified from January 1, 2004 
through June 30, 2008. Patients were assigned to fluticasone propionate/salmeterol 250/50 mcg 
combination (FSC) or anticholinergics (AC) based on their first (index) prescription. The risks 
of COPD exacerbations and healthcare utilization and costs were compared between cohorts 
during 1 year of follow-up.
Results: The adjusted risk of a COPD-related exacerbation during the 1-year follow-up period 
was 30% higher in the AC cohort (n = 2923) relative to the FSC cohort (n = 1078) (odds ratio 
[OR]: 1.30, 95% confidence interval [CI]: 1.08–1.56) after controlling for baseline differences 
in covariates. The risks of COPD-related hospitalizations and emergency department visits 
were 56% and 65% higher, respectively, in the AC cohort compared with the FSC cohort. 
The average number of COPD-related hospitalizations during the follow-up period was 46% 
higher for the AC cohort compared with the FSC cohort (incidence rate ratio [IRR]: 1.46, 95% 
CI: 1.01–2.09, P = 0.041). The savings from lower COPD-related medical costs ($692 vs $1042, 
P , 0.050) kept the COPD-related total costs during the follow-up period comparable to those 
in the AC cohort ($1659 vs $1677, P . 0.050) although the pharmacy costs were higher in the 
FSC cohort.
Conclusions: FSC compared with AC was associated with more favorable COPD-related 
outcomes and lower COPD-related utilization and medical costs among patients with COPD 
and comorbid anxiety/depression.
Keywords: COPD, fluticasone propionate/salmeterol, anticholinergics, depression, 
comorbidity
Introduction
Chronic obstructive pulmonary disease (COPD) affects an estimated 24 million individ-
uals and incurred an estimated annual $49.9 billion cost in the US in 2010.   Addressing 
this issue is important because of the increasing number of diagnosed cases.1–4 
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Neuropsychiatric symptoms and disorders including major 
depression, depressive symptoms, and anxiety are com-
monly comorbid with COPD.5,6 Estimates of prevalence 
of depression in COPD vary but are generally higher than 
those reported in some other advanced chronic diseases.5 
A cross-sectional study of 18,588 individuals in the 2004 US-
based Health and Retirement Survey found that depressive 
symptoms were more common in COPD than in coronary 
heart disease, stroke, diabetes, arthritis, hypertension, and 
cancer.7 Of the 1736 individuals with self-reported COPD, 
40% had at least three depressive symptoms. In another 
general practice study, the risk of depression was 2.5 times 
greater for patients with severe COPD than for controls with-
out COPD or asthma.8 The risk of comorbid depression was 
not increased in mild-to-moderate COPD. The authors con-
cluded that patients with severe COPD are at heightened risk 
of depression and that the results highlight the importance 
of reducing symptoms and improving physical functioning 
in patients with COPD.
Depression and anxiety in COPD may additionally 
adversely increase the burden of COPD. Depression indepen-
dently predicts poor quality of life in patients with COPD.9–11 
Depression was among several predictors of lack of adherence 
to the recommended criteria for use of inhaled corticosteroids 
in a sample of 10,711 patients with COPD in the primary care 
setting.12 Furthermore, the   presence of depression predicted 
noncompletion of pulmonary rehabilitation in COPD.13
The impact of COPD therapies on outcomes and costs 
in patients with COPD who have comorbid anxiety and/or 
depression is not fully understood. Bronchodilators (including 
beta-agonists and anticholinergics) are central to COPD 
management as they can reduce the frequency and severity 
of acute exacerbations; however, their impact in a cohort 
of COPD patients with comorbid depression has not been 
studied.14 Evidence suggests that combination long-acting 
beta agonist/inhaled corticosteroid therapy may be more 
beneficial than long-acting anticholinergic therapy with 
respect to clinical and economic outcomes.15,16 This study 
was conducted to compare the risk of COPD exacerbations 
and COPD-related health care utilization and costs between 
patients initiating inhaled corticosteroid/long-acting beta 
agonist combination therapy (fluticasone propionate/salme-
terol 250/50 mcg combination [FSC]) and those initiating 
anticholinergics (ACs) in patients with COPD and comorbid 
anxiety/depression.
Methods
Study design
Figure 1 shows the design of this observational, retrospective 
cohort study. The study period for this analysis ranged from 
January 1st, 2003 through June 30th, 2009. The popula-
tion was patients aged 40 years and older with COPD and 
comorbid depression/anxiety enrolled in health plans. The 
index date was defined as the date of the first prescription for 
maintenance COPD treatment (FSC; ACs including tiotro-
pium, ipratropium, or combination ipratropium-albuterol; 
inhaled corticosteroid; long-acting beta-agonist) during the 
period from January 1st, 2004 to June 30th, 2008, termed as 
the enrollment period. Of patients with at least one pharmacy 
claim for a maintenance medication used to treat COPD, 
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Figure 1 Study design. 
Abbreviations: FSC, fluticasone propionate/salmeterol 250/50 mcg combination; AC, anticholinergics; COPD, chronic obstructive pulmonary disease; Hosp, hospitalization; 
ED, emergency department; Phy+Rx, physician visit followed within 5 days by a prescription for an antibiotic or oral corticosteroid.
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patients were considered to have comorbid depression or 
anxiety if they had at least one prescription claim for a 
medication used to treat depression or anxiety along with a 
diagnosis code for depression during or anxiety, respectively, 
1 year pre-index or within 60 days after the index date. The 
12-month period before the index date (pre-index period) 
was used to characterize the study population at baseline, and 
the 12-month period after the index date (follow-up period) 
was used to assess all study outcomes. The first 60 days of 
the follow-up period after the index date (the clean period) 
was used to ensure receipt of monotherapy by requiring no 
use of other COPD maintenance medications. This study was 
exempt from an institutional review board approval as it was 
retrospective in nature, did not involve an intervention, and 
utilized anonymized data.
Data source
Data were obtained from the Ingenix Impact National 
  Benchmark database (formerly, IHCIS), a comprehensive US 
medical claims database generally representative of the insured 
US population aged ,65 years. The data are collected from more 
than 46 health care plans serving members across nine census 
regions. It does not include Medicaid or Medicare   information. 
The database contains inpatient/outpatient and pharmacy 
claims, lab results, and enrollment information on more than 
98 million lives from 1997 to 2010. Roughly 30.8 million 
patients in the IHCIS database have at least 2 years of both 
medical and pharmacy benefits; roughly 18.3 million patients 
have at least 3 years of both medical and pharmacy benefits. 
The data are fully de-identified and compliant with the Health 
Insurance Portability and Accountability Act.
Sample
The target population had a diagnosis of COPD (ICD-9-CM 
codes 491.xx, 492.xx, 496.xx) in any field in the pre-index 
period or 60 days after the index date; absence of exclusionary 
comorbid conditions (respiratory cancer, cystic fibrosis, fibro-
sis due to tuberculosis, and bronchiectasis, pneumoconiosis, 
pulmonary fibrosis, pulmonary tuberculosis, sarcoidosis) 
during the 1 year pre-index or post-index (follow-up) periods; 
and an index date occurring during the enrollment period.   
In addition, a diagnosis of depression or anxiety in any field, 
along with a medication for treating depression or anxiety 
was also required. Finally, patients could not have received 
maintenance medications for COPD other than the index 
medication on or 60 days after the index date and had to be 
continuously eligible to receive health care services during 
the 1-year pre-index and post-index (follow-up) periods.
Patients were categorized on the index date into the FSC 
cohort or the AC cohort depending on their medication use. 
Patients who initiated therapy with an inhaled corticosteroid or 
a long-acting beta-agonist were excluded from the study as only 
8% of the sample received these drug classes. It was thought that 
statistical and scientific conclusions based on the small number 
of patients who initiated therapy with an inhaled corticosteroid 
or a long-acting beta-agonist would not be justified.
Outcomes and costs
Clinical outcomes were risk of and number of COPD exac-
erbations during the 1-year follow-up period. A COPD exac-
erbation was defined as an emergency department visit with 
a primary diagnosis code for COPD, a hospitalization with a 
primary discharge diagnosis for COPD, or a physician visit 
with a primary diagnosis code for COPD plus a prescrip-
tion for an oral corticosteroid or antibiotic within 5 days 
of the visit. When computing the number of exacerbations, 
an exacerbation within 45 days of a previous exacerbation 
was not counted as a separate exacerbation.17 COPD-related 
total (medical plus pharmacy), medical, and pharmacy costs 
were also determined during the 1-year follow-up period and 
summed to yield annual costs, which were standardized to 
2009 $US using the Consumer Price Index for US medical 
care. COPD-related medical costs were computed from the 
paid amounts of medical claims with a primary diagnosis code 
for COPD. COPD-related pharmacy costs were computed 
from paid amounts of COPD-related prescription medica-
tions (including ACs, short-acting beta agonists, long-acting 
beta-agonists, inhaled corticosteroids, combination inhaled 
corticosteroids/long-acting beta-agonists, methylxanthines, 
oral corticosteroids, and antibiotics for respiratory infections) 
identified using national drug codes, health care common 
procedure coding system codes beginning with the letter J, or 
current procedural terminology codes as appropriate.
Cohorts were also compared with respect to pretreatment 
characteristics including demographics (age, sex, US census 
region), comorbidities during the pre-index period (Charlson 
comorbidity index score,18 asthma), and proxies for COPD 
severity during the pre-index period (number of canisters of 
inhaled short-acting beta-agonists, number of prescriptions 
for oral corticosteroids, use of home oxygen therapy, number 
of hospitalizations/emergency department visits for COPD, 
number of physician visits with a prescription for COPD). 
Age, sex, and US geographic region at the index date were 
obtained from enrollment files. The Dartmouth–Manitoba 
adaptation of the Charlson comorbidity index score18 – 
a weighted index of 19 chronic medical conditions that 
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predict mortality, postoperative complications, and length 
of hospital stay – was calculated for each patient based on 
diagnoses reported during the pre-index period (excluding 
COPD codes). The number of canisters of short-acting beta-
agonists was computed by dividing the quantity dispensed in 
mg by mg per canister. The use of home oxygen therapy was 
categorized as a binary variable (use, no use) based on current 
procedural terminology codes for home oxygen therapy on 
medical claims.
Statistical analysis
Pretreatment characteristics were summarized with 
descriptive statistics. Inferential statistics (chi-square test 
for categorical variables, t-test or Mann–Whitney test for 
continuous variables) were used to quantify differences 
between cohorts.
Multivariate regression models were used to examine the 
association between the initiation of index drugs and outcomes 
while controlling for potential confounders. Covariates were 
chosen a priori for all models on the basis of clinical   relevance 
and significant differences at baseline. The covariates 
were age, male gender, Charlson comorbidity index, upper 
respiratory tract infection, cardiovascular disease, asthma, 
presence of short-acting beta-agonist, presence of oral corti-
costeroid, presence of home oxygen therapy, and presence of 
COPD-related hospitalizations. A logistic regression model 
was used to analyze differences between cohorts in the risk 
of COPD exacerbations. A zero-inflated negative binomial 
regression model was used to analyze differences between 
cohorts in the number of COPD-related exacerbations.
Differences between cohorts in COPD-related costs were 
evaluated with a generalized linear model using a gamma 
distribution with a log link function while controlling for 
covariates. This method has the advantage of estimating the 
adjusted costs directly without the need for retransforma-
tion while simultaneously using log-transformed costs in its 
estimation. The method of recycled predictions was used to 
obtain predicted costs for each cohort.
Results
Sample
Among patients with a diagnosis of COPD and a prescription 
filled for COPD maintenance medications during the study 
period, 34,189 (11.5%) patients had a diagnosis of depression 
or anxiety and a prescription filled for depression or anxiety 
medications between 1 year pre-index and 60 days post-
index date. Of these 34,189 patients, 30,188 (88.3%) were 
excluded from the study mainly because of noncontinuous 
eligibility (44.4%) and no COPD diagnosis (25.5%) during 
the pre-index period through 60 days after the index date. 
After applying exclusion criteria, the final sample comprised 
4001 patients (n = 1078 FSC; n = 2923 AC).
Table 1 shows demographics and pre-index clinical 
characteristics, health care use, and costs. In the FSC cohort 
compared with the AC cohort, patients were younger, more 
likely to be female, had lower Charlson comorbidity index 
at baseline, and were more likely to have asthma. Pre-index 
COPD was more severe in the FSC cohort than the AC cohort 
reflected by the higher use of short-acting beta-agonist canis-
ters and oral corticosteroid prescriptions. During the 1-year 
pre-index period, the proportion of patients having a COPD-
related hospitalization and COPD-related medical costs was 
significantly lower in the FSC cohort than the AC cohort. 
Pre-index COPD-related pharmacy costs were significantly 
higher for the FSC cohort than the AC cohort.
Clinical and economic outcomes
Unadjusted outcomes
Table 2 shows unadjusted data on COPD-related outcomes 
and costs. In the unadjusted dataset, the proportion of patients 
with any COPD-related exacerbation in the follow-up 
period was lower in the FSC cohort compared with the AC 
cohort (18.6% vs 23.1%, P = 0.002). The annual number of 
COPD-related hospitalizations was significantly lower for 
the FSC cohort compared with the AC cohort (0.04 vs 0.07, 
P , 0.001). Despite higher annual COPD-related phar-
macy costs in the FSC cohort compared with the AC cohort 
(US$934 vs US$684, P , 0.001), COPD-related annual total 
costs (US$1604 vs US$1687, P , 0.001) were significantly 
lower for the FSC cohort driven because of lower medical 
costs (US$670 vs US$1003, P = 0.001).
Adjusted outcomes
After controlling for differences in baseline covariates 
between the cohorts, the adjusted overall risk of having any 
COPD-  related exacerbation during the 1-year follow-up 
period was 30% higher in the AC cohort relative to the FSC 
cohort (odds ratio [OR]: 1.30, 95% confidence interval [CI]: 
1.08–1.56) (Figure 2). The risks of COPD-related hospital-
izations and emergency department visits were 56% and 
65% higher, respectively, in the AC cohort compared with 
the FSC cohort (Figure 2).
The average number of COPD-related hospitaliza-
tions during the 1-year follow-up period was 46% 
higher for the AC cohort compared with the FSC cohort 
(incidence rate ratio [IRR]: 1.46, 95% CI: 1.01–2.09,   
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P = 0.041). The average number of combined COPD-related 
hospitalizations and emergency department visits was 31% 
higher in the AC cohort compared with the FSC cohort 
(IRR: 1.31, 95% CI: 1.05–1.72, P = 0.045). The cohorts 
did not differ significantly with respect to the numbers 
of COPD-related emergency department visits or COPD-
related physician office visits with an oral corticosteroid/
antibiotic dispensed within 5 days of the visit.
Table 3 shows adjusted COPD-related costs by cohort. 
The savings from lower COPD-related medical cost (US$692 
vs US$1042, P , 0.050) kept the COPD-related total costs 
during the 1-year follow-up period comparable to those in 
the AC cohort (US$1659 vs US$1677, P . 0.050) although 
the FSC group had higher COPD-related pharmacy costs 
(US$941 vs US$683, P , 0.050).
Discussion
This study is, to the authors’ knowledge, the first to assess 
a cohort of COPD patients with comorbid anxiety/depres-
sion initiating maintenance therapy with FSC or AC. The 
use of FSC was associated with better clinical and economic 
COPD-related outcomes. The AC cohort compared with the 
FSC cohort had a significantly higher risk of experiencing 
any COPD-related exacerbation, exacerbations requiring 
hospitalization, and exacerbations requiring an emergency 
department visit during the 1-year study period. The number 
of COPD-related hospitalizations was lower for patients who 
initiated COPD maintenance therapy with FSC compared 
with AC. The lower risks of COPD-related hospitalizations 
and emergency department visits and the lower number of 
hospitalizations in the FSC cohort were associated with a 
Table 1 Baseline characteristics
Characteristics Total 
(n = 4001)
FSC 
(n = 1078)
AC 
(n = 2923)
P value
Demographics
Age in years (mean, SD) 59.6 (10.2) 57.8 (9.8) 60.3 (10.3) ,0.001
Female (n, %) 2652 (66.3%) 742 (68.8%) 1910 (65.3%) 0.038
Region (n, %)             0.539
  Northeast 1580 (39.5%) 437 (40.5%) 1143 (39.1%)  
  Midwest 701 (17.5%) 174 (16.1%) 527 (18.0%)  
  South 1279 (32.0%) 350 (32.5%) 929 (31.8%)  
  West 441 (11.0%) 117 (10.9%) 324 (11.1%)  
Overall disease burden (1-year pre-index)
Charlson index (mean, SD) 2.2 (2.5) 2.0 (2.2) 2.2 (2.6) 0.006
Upper respiratory tract infection (n, %) 1287 (32.2%) 400 (37.1%) 887 (30.4%) ,0.001
Lower respiratory tract infection (n, %) 1707 (42.7%) 448 (41.6%) 1,259 (43.1%) 0.390
Cardiovascular disease (n, %) 2,743 (68.6%) 694 (64.4%) 2,049 (70.1%) 0.001
Asthma (n, %) 904 (22.6%) 367 (34.0%) 537 (18.4%) ,0.001
COPD severity (1-year pre-index)
Number of short-acting beta-agonist canisters (mean, SD) 0.8 (2.4) 1.0 (2.8) 0.7 (2.2) 0.001
Use of short-acting beta-agonist (n, %) 1111 (27.8%) 384 (35.6%) 727 (24.9%) ,0.001
Number of oral corticosteroid prescriptions (mean, SD) 0.6 (1.4) 0.7 (1.4) 0.5 (1.4)
Use of oral corticosteroid (n, %) 1129 (28.2%) 366 (34.0%) 763 (26.1%) ,0.001
Use of home oxygen therapy (n, %) 343 (8.6%) 77 (7.1%) 266 (9.1%) 0.050
Hospitalization/emergency visit for COPD (n, %) 382 (9.6%) 89 (8.3%) 293 (10.0%) 0.091
Hospitalization 231 (5.8%) 49 (4.6%) 182 (6.2%) 0.043
Emergency department visit 177 (4.4%) 49 (4.6%) 128 (4.4%) 0.820
Number of office visits with a prescription for COPD (mean, SD) 0.1 (0.4) 0.1 (0.4) 0.1 (0.4) 0.977
COPD-related costs (1-year pre-index)
Total (mean, SD) $1150 ($4720) $977 ($3774) $1213 ($5023) 0.559
Pharmacy (mean, SD) $139 ($219) $161 ($233) $131 ($214) ,0.001
Medical (mean, SD) $1010 ($4701) $817 ($3740) $1082 ($5007) 0.021
  Hospitalization $640 ($3,943) $543 ($3534) $676 ($4083) 0.058
  Emergency department visit $51 ($437) $39 ($289) $55 ($480) 0.843
  Physician visit $72 ($175) $73 ($174) $72 ($176) 0.908
  Outpatient visit $81 ($401) $65 ($307) $87 ($431) 0.093
  Other $166 ($2302) $97 ($866) $191 ($2640) 0.005
Note: Bold values indicate statistically significant difference between cohorts (P , 0.050); all costs in USD. 
Abbreviations: FSC, fluticasone propionate/salmeterol 250/50 mcg combination; AC, anticholinergics; SD, standard deviation; COPD, chronic obstructive pulmonary disease.
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reduction in COPD-related medical costs for the FSC cohort 
compared with the AC cohort.
In clinical studies comparing FSC and tiotropium, lung 
function improvements and exacerbation rates were similar 
whereas quality of life was better in the FSC groups.19 In 
addition, patients taking inhaled corticosteroids tended to 
have fewer exacerbations that required treatment with oral 
corticosteroids compared with subjects taking tiotropium. 
These differences (ie, an improved quality of life and a 
reduction in dyspnea during exacerbations) may reflect the 
effects of the inhaled corticosteroid-associated improve-
ment in health in these patients and may help to explain 
why this therapy might improve outcomes in a depressed 
population.
The present study adds to a body of literature, from 
studies of patients with COPD selected without regard 
to the presence of comorbid depression, that supports 
the benefits of FSC versus both short- and long-acting 
anticholinergic bronchodilators in reducing the risk of 
COPD-related events and/or reducing medical and total 
costs.16,20–22 In an observational study of 14,689 patients 
aged $65 years with COPD in a commercial Medicare 
health maintenance organization plan, initial maintenance 
treatment with FSC was associated with total COPD-related 
cost savings (medical plus pharmacy) of US$110 versus 
tiotropium, US$295 versus ipratropium/albuterol, and 
US$1235 versus ipratropium (all of which are ACs) over 
a 1-year follow-up period.16 This reduction in total costs 
Table 2 Unadjusted COPD-related outcomes and costs for patients receiving FSC versus AC
Outcome FSC 
(n = 1078)
AC 
(n = 2923)
P value
Risk of COPD exacerbation (n, %)          
Hospitalization 35 (3.3%) 168 (5.8%) 0.002
Emergency department visits 37 (3.4%) 171 (5.9%) 0.002
Phy+Rx 156 (14.5%) 448 (15.3%) 0.503
Hospitalization/emergency department visit 63 (5.8%) 307 (10.5%) ,0.001
Hospitalization/emergency department visit/Phy+Rx 200 (18.6%) 674 (23.1%) 0.002
Number of COPD exacerbations (mean, SD)          
Hospitalization 0.04 (0.2) 0.07 (0.3) ,0.001
Emergency department visits 0.06 (0.4) 0.07 (0.4) 0.208
Phy+Rx 0.19 (0.6) 0.20 (0.6) 0.671
Hospitalization/emergency department visit 0.09 (0.5) 0.14 (0.5) 0.009
Hospitalization/emergency department visit/Phy+Rx 0.29 (0.8) 0.34 (0.8) 0.052
COPD-related annual costs (mean, SD)
Total costs $1604 ($3187) $1687 ($4299) ,0.001
Pharmacy costs $934 ($814) $684 ($724) ,0.001
  Index drug $636 ($612) $397 ($471) ,0.001
  Other study drug $298 ($475) $287 ($478) 0.529
Medical costs $670 ($2923) $1003 ($4095) 0.001
  Hospitalization $229 ($1983) $453 ($3543) 0.001
  Emergency department visit $44 ($438) $51 ($356) 0.003
  Physician visit $127 ($361) $133 ($257) 0.335
  Outpatient visit $113 ($562) $162 ($680) 0.014
  Other $158 ($1203) $206 ($1126) ,0.001
Note: Bold values indicate statistically significant difference between cohorts (P , 0.050); all costs in USD. 
Abbreviations: COPD, chronic obstructive pulmonary disease; FSC, fluticasone propionate/salmeterol 250/50 mcg combination; AC, anticholinergics; Phy+Rx, physician 
visit followed within 5 days by a prescription for an antibiotic or oral corticosteroid; SD, standard deviation.
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Figure 2 Risk of COPD exacerbations in the AC cohort relative to the FSC cohort 
(reference group). 
Note: *P,0.050; ORs were derived from logistic regression models.
Abbreviations: COPD, chronic obstructive pulmonary disease;  AC, anticholinergics; 
FSC, fluticasone propionate/salmeterol 250/50 mcg combination; OR, odds ratio; 
Hosp,  hospitalization;  ED,  emergency  department  visit;  Phy+Rx,  physician  visit 
followed within 5 days by a prescription for an antibiotic or oral corticosteroid.
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with FSC versus tiotropium more than offsets the higher 
pharmacy costs of FSC. In a retrospective, observational 
study involving Texas Medicaid beneficiaries aged 40 to 
64 years (n = 6793), FSC compared with ipratropium was 
associated with a 27% lower risk of COPD-related hospi-
talization or emergency department visit and with similar 
COPD-related total costs (medical plus pharmacy costs) 
over 12 months.20 In another study, initial maintenance 
therapy with FSC compared with ipratropium was associ-
ated with a 56% lower risk of COPD-related hospitalization 
or emergency department visit and similar COPD-related 
total costs (with lower all-cause total costs) in patients 
$40 years with COPD.21 Finally, in a retrospective claims 
analysis involving 1051 adults $65 years with COPD, 
FSC compared with ipratropium was associated with a 
45% reduction in the risk of COPD-related hospitaliza-
tion or emergency department visit, and lower COPD-
related medical costs.22 In several of these studies,16,21,22 
FSC-associated reductions in medical costs appeared to 
more than offset the increase in pharmacy costs such that 
total costs (medical plus pharmacy) were lower with FSC 
(although total costs were not reported in one study);21 
however, pharmacy costs were higher with FSC than with 
the short-acting anticholinergic bronchodilator. Across 
studies comparing FSC with short- and long-acting anticho-
linergic bronchodilators in patients selected without regard 
to presence of comorbid depression, FSC was associated 
with significantly lower risk of COPD-related events and, 
generally, lower total medical costs.
In the current study, definitions for COPD exacerba-
tions included emergency department visits, hospitaliza-
tions, and physician visits with a prescription for an oral 
corticosteroid or antibiotic for respiratory infections. A 
similarly inclusive definition was used in recent studies 
of COPD exacerbations.23–26 Emergency department visits 
and hospitalizations reflect severe exacerbations, and phy-
sician visits with a prescription for an oral corticosteroid 
or antibiotic may reflect moderate exacerbations. The use 
of these definitions for COPD exacerbations provides a 
sensitive measure of treatment outcomes and reflects the 
spectrum of manifestations of COPD exacerbations in 
clinical practice.
The results of this study should be interpreted in the 
context of its limitations. Although analyses controlled for 
differences in baseline disease severity and other baseline 
characteristics in both adjusted cost models and risk models 
in the current study, such adjustment is imperfect and does 
not obviate the need for further assessment in cohorts bal-
anced with respect to baseline characteristics. The possibil-
ity remains of residual confounding due to between-cohort 
differences in patient characteristics that were not controlled 
for in multivariate analysis. Other limitations of this study 
include potential errors in the coding of claims, the inability 
to verify the accuracy of diagnosis codes, and the absence 
of a means of assessing patient compliance. The potential 
for these biases is inherent in observational studies. If these 
biases were operating, they are likely to have been operating 
similarly between cohorts.
Patients with COPD are at increased risk of depression 
and anxiety relative to those with other chronic disorders.5–7 
This observational study is believed to be the first to examine 
the impact of pharmacotherapy on outcomes and costs in 
patients with COPD and depression or anxiety. The results 
show that FSC compared with AC was associated with more 
favorable COPD-related outcomes and lower COPD-related 
utilization and medical costs among patients with COPD and 
comorbid depression or anxiety. Further study of the influ-
ence of therapeutic intervention on outcomes, utilization, 
and costs in COPD and comorbid depression or anxiety is 
warranted.
Table 3 Adjusted COPD-related costs by cohort
Cost outcome FSC AC Difference (95% CI)
Mean 95% CI Mean 95% CI
COPD-related costs
Total costs $1659 ($757, $3754) $1677 ($710, $4087) -$18 ($47, -$333)
Pharmacy costs $941 ($526, $1708) $683 ($360, $1315) $258 ($167, $392)
Medical costs $692 ($84, $4377) $1042 ($103, $7511) -$350 (-$19, -$3134)
  Hospitalization $231 ($5, $2118) $446 ($7, $4538) -$215 (-$2, -$2420)
  Emergency department visit $46 ($3, $502) $50 ($2, $525) -$4 ($1, -$23)
  Physician visit $128 ($25, $477) $132 ($21, $554) -$5 ($4, -$77)
  Outpatient visit $118 ($4, $2651) $156 ($4, $4503) -$38 ($0, -$1852)
  Other $176 ($21, $790) $199 ($20, $908) -$23 ($1, -$118)
Notes: Bold values indicate statistically significant difference between cohorts (P , 0.05); all costs in USD. 
Abbreviations: COPD, chronic obstructive pulmonary disease; FSC, fluticasone propionate/salmeterol 250/50 mcg combination; AC, anticholinergics; CI, confidence interval.
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